Primary IOL implantation is successful in children under 2 years of age

Article

The implantation of intraocular lenses (IOL) is a safe and effective option for visual rehabilitation in children under 2 years of age, according to findings published in the British Journal of Ophthalmology.

The implantation of intraocular lenses (IOL) is safe and effective option for visual rehabilitation in children under 2 years of age, according to findings published in the British Journal of Ophthalmology.

Dr Ramesh Kekunnaya et al., Jasti V Ramanamma Children's Eye Care Center, Hyderabad, India, collected data from 120 eyes of 80 children with congenital/developmental cataract who underwent surgery between January 2006 and December 2007. Of the 120 eyes, 31 were operated on before they were 6 months of age and 89 eyes were operated on after 6 months of age. Rigid polymethylmethacrylate lenses were implanted in 30 eyes and acrylic hydrophobic foldable lenses were implanted in 90 eyes.

Five eyes demonstrated increased anterior chamber inflammation, 8 eyes experienced opacification of the visual axis, 2 eyes had decentration of IOL, 4 eyes experienced pigment dispersion on IOL and posterior synechiae were recorded in 5 eyes.

At the last follow-up there were no cases of glaucoma and no cases of endophthalmitis and retinal detachment. It was concluded that the implantation of IOLs in children below 2 years of age is a viable method for visual performance enhancement.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Andreas Pollreisz, MD, discusses widefield OCT-A and fluorescence angiography at the 2025 European Society of Retina Specialists EURETINA meeting
Harvey Uy, MD, DPBO, FVRSP, speaks about artificial intelligence (AI) and optical coherence tomography (OCT) at the 2025 European Society of Retina Specialists (EURETINA) Congress.
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
© 2025 MJH Life Sciences

All rights reserved.